Economic implications of novel regimens for tuberculosis treatment in three high-burden countries: a modelling analysis
Ryckman T, Schumacher S, Lienhardt C, Sweeney S, Dowdy D, Mirzayev F, Kendall E. Economic implications of novel regimens for tuberculosis treatment in three high-burden countries: a modelling analysis. The Lancet Global Health 2024, 12: e995-e1004. PMID: 38762299, PMCID: PMC11126367, DOI: 10.1016/s2214-109x(24)00088-3.Peer-Reviewed Original ResearchConceptsRifampin-resistant tuberculosisRifampin-susceptible tuberculosisMedium-term costsTuberculosis treatmentRifampin susceptibilityTuberculosis regimensStandard-of-care regimensCost-effective priceEstimated pricePrice thresholdsPriceDrug costsCost-neutralNovel drug combinationsStandard-of-careSouth AfricaTuberculosis treatment regimensEconomic implicationsStandard of carePatient-borne costsHigh-burden countriesCohort of adultsDecision-analytic modelShorter regimensNovel regimens